is provided by the patient. 27 Data on patient and tumor characteristics, treatment, and survival were extracted from the Netherlands Cancer Registry (NCR), which is a population-based registry that covers the total Dutch population of >17 million
Search Results
Willemieke P.M. Dijksterhuis, Anouk E.J. Latenstein, Jessy Joy van Kleef, Rob H.A. Verhoeven, Jeanne H.M. de Vries, Marije Slingerland, Elles Steenhagen, Joos Heisterkamp, Liesbeth M. Timmermans, Marian A.E. de van der Schueren, Martijn G.H. van Oijen, Sandra Beijer, and Hanneke W.M. van Laarhoven
Yue Chen, Zi-Qi Zheng, Fo-Ping Chen, Jian-Ye Yan, Xiao-Dan Huang, Feng Li, Ying Sun, and Guan-Qun Zhou
the role of PORT in survival outcome, which would help surgeons and radiologists provide individualized recommendations regarding PORT to patients with ACC. Patients and Methods Patient Characteristics From January 2000 through December 2017, 480
Matthew G. Fury, Eric Sherman, Donna Lisa, Neeraj Agarwal, Kenneth Algazy, Bruce Brockstein, Corey Langer, Dean Lim, Ranee Mehra, Sandeep K. Rajan, Susan Korte, Brynna Lipson, Furhan Yunus, Tawee Tanvetyanon, Stephanie Smith-Marrone, Kenneth Ng, Han Xiao, Sofia Haque, and David G. Pfister
more of the first 18 patients (each group treated separately) experienced a dose-limiting toxicity (as defined in the protocol) during cycle 1 or 2, that group would be closed because of excess toxicity. Results Patient Characteristics The
Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, and Peter A. Fasching
4 RCTs, carboplatin in 3 RCTs, and nab-paclitaxel, everolimus, and anthracycline in 1 RCT each. Different pCR definitions were used across trials, of which ypT0/is ypN0 was the most common. The characteristics of the included trials are listed in
Amy A. Kirkham, Karen A. Gelmon, Cheri L. Van Patten, Kelcey A. Bland, Holly Wollmann, Donald C. McKenzie, Taryne Landry, and Kristin L. Campbell
Baseline characteristics were compared between groups using independent t tests and chi-square tests. Relative risk (RR; with 95% confidence intervals and number needed to treat [NNT]) was used to compare categorical metrics of treatment tolerance
Lucas K. Vitzthum, Chris Straka, Reith R. Sarkar, Rana McKay, J. Michael Randall, Ajay Sandhu, James D. Murphy, and Brent S. Rose
year before PCa diagnosis as previously described. 15 , 16 Table 1. Patient and Tumor Characteristics Information on treatment with ADT was obtained from the VA pharmacy database. CAB was defined as treatment with a nonsteroidal androgen receptor
Omar Abdel-Rahman
important to guide health authorities and practitioners to provide a personalized cancer survivorship message (according to individual characteristics) instead of the currently available generic messages and advice that do not take into consideration the
Jeffrey M. Martin, Tianyu Li, Matthew E. Johnson, Colin T. Murphy, Alan G. Howald, Marc C. Smaldone, Alexander Kutikov, David Y.T. Chen, Rosalia Viterbo, Richard E. Greenberg, Robert G. Uzzo, and Eric M. Horwitz
univariate analyses were performed. Results From 2003 to 2011, 475 patients received PPRT at FCCC (83 adjuvant and 392 salvage). The patient characteristics and descriptives are listed in Table 1 . Patients were more likely to receive adjuvant RT if
Eric J. Roeland, Kathryn J. Ruddy, Thomas W. LeBlanc, Ryan D. Nipp, Gary Binder, Silvia Sebastiani, Ravi Potluri, Luke Schmerold, Eros Papademetriou, Lee Schwartzberg, and Rudolph M. Navari
We analyzed patient characteristics, HEC courses, and clinician practice patterns using descriptive statistics. Clinician HEC CINV prophylaxis adherence was categorized into deciles for each HEC, noting the clinicians with ≤90% adherence. Variability
Arif Kamal, Tian Zhang, Steve Power, and P. Kelly Marcom
patients with cancer and the noncancer control population, a chi-square test was performed. Univariate logistic regression was used to determine patient and disease characteristics associated with the ordering of imaging. For determination of the attribute
